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Abstract
Advances in biomedical research allow for the capture of an unprecedented level of genetic, molecular, and
clinical information from large patient cohorts, where the quest for precision medicine can be pursued. An
overarching goal of precision medicine is to integrate the large–scale genetic and molecular data with deep
phenotypic information to identify a newmechanistic disease classification. This classification can ideally be used
to meet the clinical goal of the right medication for the right patient at the right time. Glomerular disease
presents a formidable challenge for precision medicine. Patients present with similar signs and symptoms, which
cross the current disease categories. The diseases are grouped by shared histopathologic features, but individual
patients have dramatic variability in presentation, progression, and response to therapy, reflecting the underlying
biologic heterogeneity within each glomerular disease category. Despite the clinical challenge, glomerular dis-
ease has several unique advantages to building multilayered datasets connecting genetic, molecular, and struc-
tural information needed to address the goals of precision medicine in this population. Kidney biopsy tissue,
obtained during routine clinical care, provides a direct window into the molecular mechanisms active in the
affected organ. In addition, urine is a biofluid ideally suited for repeated measurement from the diseased organ as
a liquid biopsy with potential to reflect the dynamic state of renal tissue. In our review, current approaches for
large–scale data generation and integration along the genotype-phenotype continuum in glomerular disease will
be summarized. Several successful examples of this integrative biology approachwithin glomerular diseasewill be
highlighted along with an outlook on how achieving a mechanistic disease classification could help to shape
glomerular disease research and care in the future.
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Introduction
The last decade has seen rapid advances in biomedical
research, now allowing the capture of genetic, molec-
ular, and clinical information from large patient
cohorts. These advances motivated the strategy pro-
posed in the 2011 Institute of Medicine (IOM) report
Toward Precision Medicine: Building a Knowledge Network
for Biomedical Research and a New Taxonomy of Disease
(1). This strategy aims to use prospective cohorts of
patients under routine clinical care to map genetic
and molecular profiles with clinical disease course.
The overarching goal is to use large–scale data integra-
tion paired with deep phenotypic clinical data to
establish a disease classification (i.e., a new taxonomy)
rooted in molecular causes as well as clinical presenta-
tion. The approach of precision medicine, endorsed
by a major initiative from the National Institutes of
Health (NIH) (2), strives to achieve the goal of targeted
treatment assignment. Precision medicine in this con-
text takes into account individual disease presentation
and variability in mechanistic terms to realize the con-
cept of the right medication for the right patient at the
right time.
This concept of precision nephrology certainly reso-
nates with patients affected by glomerular disease and
the health providers caring for them. Patients present
with multiple signs and symptoms (e.g., edema, pro-
teinuria, hematuria, and reduced renal function),
which cross the current disease categories. At the
same time, patients grouped into a common diagnosis
by histopathologic features often have dramatic vari-
ability in presentation, progression, and response to
therapy. The mainstay of therapy includes immuno-
suppressive drugs, which have an unpredictable re-
sponse at the individual patient level and frequent
toxicity (3–5). These clinical observations are a direct
consequence of the underlying biologic heterogeneity
within each glomerular disease currently lumped to-
gether by our descriptive classifications. The applica-
tion of precision medicine to glomerular disease
provides an opportunity to identify molecular predictors
of underlying disease mechanisms, response to therapy,
and progression of disease. Combined with currently
available clinical and pathologic features as well as
validating the findings in model systems, this approach
ultimately strives to inform treatment decisions and
improve patient outcomes.
The field of oncology is commonly looked to as a
model of success in leveraging this approach to not
only better understand disease heterogeneity but also,
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translate such insights into novel therapies (6). The success-
ful use of whole-exome sequencing to identify the genetic
basis for response to cytotoxic T-lymphocyte antigen 4
blockade in melanoma is one such example (7). In this land-
mark study, a discovery cohort of only 25 patients (11 who
responded to therapy and 14 who did not) was analyzed
through a bioinformatic pipeline, which included sequenc-
ing for mutational load in the tumor tissue, translating
mutations into altered peptides, and simulating MHC class
1 binding, leading to the identification of a neoepitope sig-
nature that correlated with clinical response. Furthermore,
the Cancer Genome Atlas (TCGA) aims to establish a core
resource to facilitate this approach in other cancer diagno-
ses. TCGA is funded by the National Cancer Institute and
the National Human Genome Research Institute and has
collected tumor and normal tissue from 11,000 patients
with 33 types of cancer to generate multiple large–scale
databases of DNA, RNA, and proteomics. Among other
advances, this database was used to identify biologically
based subtypes of glioblastoma, setting up improved trial
design, and enabling novel therapeutic developments (8,9).
This article will highlight definitions, important limita-
tions, and approaches to large–scale dataset generation in
glomerular disease (excluding genetics, which will be dis-
cussed separately in this series). Examples of the successful
application of an integrative approach in glomerular dis-
ease will be provided, with the anticipation that more suc-
cess stories are expected in the future. The power of
analyzing the human disease as a unified whole has inde-
pendent value, but combining with parallel work in model
systems, cell cultures, and observational and interven-
tional clinical studies allows each approach to inform the
other and expedite discovery and clinical translation.
Generation of Large-Scale Data in Glomerular
Disease
Generation of multilayered large–scale datasets for glo-
merular disease begins to address the goals of precision
medicine for nephrology (Figure 1). Not unlike oncology,
there are unique advantages of applying this approach to
kidney disease, where the biospecimens needed to gener-
ate the datasets highlighted in Figure 1 are frequently ob-
tained during routine clinical care. For example, biopsy
tissue (morphology) not only provides valuable structural
information currently in clinical use, but also offers a win-
dow into the molecular mechanisms active in the tissue of
the affected organ (transcriptome). Another advantage is
the easy access to urine, which can be tested repeatedly
and serves as a potential liquid biopsy to capture changes
Figure 1. | Large–scale dataset integration across the genotype-phenotype continuum. Integrative biology approaches can be initiated with
any dataset across the genotype-phenotype continuum and then, evaluated against the other domains to help identify novel risk factors,
pathogenic pathways, or biomarkers of progression and therapeutic response. As a result, novel mechanisms can be further investigated in
model systems to confirmfindings and test therapies.Mechanistic–based patient groups can be identified and targeted for enrollment in proof of
concept clinical trials.
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in the renal tissue with high precision (proteome and
metabolome).
Epigenetics
Epigenetics generally refers to changes in nucleic acids
of a given cell or cell type and its descendants that do not
involve alteration in the underlying DNA sequence. Epi-
genetic modifications include DNA methylation, histone
modification, and noncoding RNA (e.g., microRNAs),
which can activate or silence genes. These modifications
help to explain why a given transcription factor may have
different effects in different cell types (10). These changes
may be induced by aging and environmental exposures
and have been linked to many chronic diseases (10,11).
There are multiple methods to generate epigenetic datasets
that capture the variety of modifications, but in general,
they can be assessed in a genome-wide fashion using se-
quencing (e.g., bisulfite-seq) or microarrays. As with other
large–scale datasets, the generation method has advantages
and disadvantages, including coverage of the genome, quan-
titative information availability, and resolution (11). Of note,
epigenetic changes in the kidney vary by cell type and may
change over time, and should be accounted for in the anal-
ysis of this type of data.
Transcriptomics
Transcriptomics refers to the set of mRNA produced by
the genome in a cell or tissue. Also referred to as gene ex-
pression, it is the integrated response of a cellular system
to its environment and can vary widely by cell type, by
tissue type, by disease state, and in response to treatment.
As a result, it is far more dynamic than the epigenome.
These data can be obtained from prospectively procured
or archival tissue samples and analyzed by quantitative
PCR for transcripts of interest, microarrays that can detect
thousands of transcripts and transcript-wide sequencing
(e.g., RNA-seq). Expression profiles can be analyzed at the
specific transcript level, or prior knowledge can be used to
aggregate transcripts known to interact in functional
groups for association with disease groups or clinical dis-
ease progression (12). Of note, the mRNA levels may not
necessarily correlate with actual protein levels given the
additional regulation of protein production, modification,
and degradation. Also, mRNA analysis at the tissue level
will be affected by the cell composition. Newer techniques,
such as Drop-seq, can generate single–cell transcription
profiles (13).
Proteomics
Proteomics, including phospho- and glycoproteomics,
aims to capture the complexity of the human protein
machinery, which further exceeds that of the genome by
several orders of magnitude. Proteomics refers to the com-
plete set of proteins expressed within a cell, tissue, or
organism. Detection approaches have diversified substan-
tially ranging from antibody–based, targeted strategies
(identification of a previously known protein) to unbiased
mass spectrometry profiling (screening proteins that may
or may not have previously been identified). Microarrays
and suspension-bead assays can detect multiple proteins
in a single analysis. Detection depth is increasing steadily
to capture several thousand molecules per analysis run but
has not reached the same comprehensive level as for nu-
cleic acids. Proteomic analysis of serum, plasma, urine,
and kidney tissue is readily possible and may ultimately
prove fruitful in numerous forms of glomerular disease
with regard to unbiased biomarker discovery (14). How-
ever, each approach has its set of limitations, including
that more abundant proteins are more easily identified,
that mapping of peptides to proteins remains imperfect,
and that results may be influenced by various methods of
protein extraction and purification before analysis. That
said, proteomic analyses were critical to identifying phos-
pholipase A2 receptor (PLA2R) as the key antigen in id-
iopathic membranous nephropathy (MN) (15), and a
comparison of the proteome of urinary microvesicles
from patients with idiopathic MN, patients with FSGS,
and healthy controls revealed a potential association of
increased lysosome membrane protein-2 as a biomarker
in idiopathic MN (16).
Metabolomics
Metabolites (i.e., amino acids, bile acids, organic acids,
and sugars) are the downstream products of enzymatic
activity and considered the “currency of the cell,” reflect-
ing the metabolic state of an organism. Most currently
used biochemical markers of renal function fall into this
category (e.g., creatinine, urea, uric acid, and cystatin C).
They represent not only the active biologic processes, but
they are also thought to have possible functional roles in
health and disease (17). Metabolomics datasets can be gen-
erated using high–field nuclear magnetic resonance spec-
troscopy or mass spectrometry to separate and detect
metabolites followed by data processing and bioinformat-
ics analyses for identification (18,19). Targeted approaches
can be used to identify a smaller number of metabolites
with high accuracy. Finally, separate approaches, using
heavy isotope–labeled substrates, allow for analysis of
the amount of a metabolite derived from a particular sub-
stance or cellular pathway (20). Of note, metabolites are
very diverse biochemical entities, and no single platform is
able to capture the full spectrum given their chemical di-
versity, huge range of observed concentrations, and vari-
ations by cell and tissue type. Additionally, metabolites
can be alternated by environmental exposures (e.g., food,
medication, or microbes), which vary by person (20).
Microbiomics
Microbiomics captures the commensal flora present on
and in the human body, most often by identification of
known microbe DNA or RNA. There has been limited
application of microbiomics to glomerular disease with re-
gard to analysis of flora from different areas of the body,
including but not limited to saliva and stool (21). However,
with an increased understanding of the tight interaction of
the resident human flora with a multitude of physiologic
functions ranging from immune response to metabolism,
discoveries could be made in glomerular diseases that
have strong pathogenetic associations with intestinal flora
and the immune system. This connection is starting to be
made with regard to IgA nephropathy, and a recent study
provides the first evidence in support of an association of
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stool microbiota in patients with and without progressive
IgA nephropathy (22).
Large–Scale Data Capture for Structural, Clinical, and
Environmental Measures
Structural information from tissue biopsies has been the
prime source of disease classification of glomerular dis-
eases. The rich visual information can now be captured by
digital whole–slide imaging and made accessible to data
mining tools used for the genetic and molecular informa-
tion described above (23). These images can be accessed
remotely for analysis by pathologists for systematic scoring,
morphometric measurements, and potentially, computer–
assisted image analysis.
With the mandated implementation of electronic health
records in routine care, data sources for clinical informa-
tion are starting to match the scale and complexity of the
genetic and molecular datasets described above. A detailed
discussion of research using electronic health records, its
opportunities, and its challenges is beyond the scope of this
review. However, it is noted that simplifying the ability to
easily extract, annotate, and understand unstructured clin-
ical data from electronic health records through natural
language processing has been developed and is starting to
be deployed for renal diseases (24).
Comprehensive capture of glomerular disease etiologies
should also include the definition of potential environ-
mental determinants. Approaches that link environmental
exposures to defined neighborhoods on a national scale,
referred to as “geomapping,” can be used to effectively eval-
uate the interaction of the environment with genetic and
molecular disease determinants (25).
Team Science and Data Integration
One of the main opportunities and challenges of an in-
tegrative biology approach is the wide range of research
approaches deployed and data types generated as noted
above. This mandates investigative teams with the ability
to integrate diverse research strategies and expertise. This
team science approach maximizes the potential of any indi-
vidual multilayered dataset by analyses conducted across
the different data domains, facilitating discovery of novel
associations and disease mechanisms (26).
Making the large-scale data accessible to the research
teams and in particular, researchers collaborating outside
of their domain expertise is an essential step of the pre-
cision medicine approach, but it requires unique tools
to facilitate the engagement of the scientific community.
Indeed, the 2015 IOM report on team science highlighted
diversity of expertise in team membership and deep knowl-
edge integration as two of the key challenges for team science
in precision medicine (27).
Several approaches have been developed for exploration
of large-scale datasets from renal disease and are currently
used by the community. One example is Nephroseq, a web-
based tool designed to make gene expression datasets
readily searchable by researchers with a wide range of ex-
pertise. Renal gene expression datasets are obtained from
the public domain, such as with Gene Expression Omnibus
(National Center for Biotechnology Information; www.
ncbi.nlm.nih.gov/geo), or directly from investigators,
annotated against a standardized ontology, and loaded
into Nephroseq. The datasets are linked and dynamically
analyzed with a wide variety of systems biology tools. Users
can search the datasets by a single gene, a list of genes, or a
predefined gene list to conduct a variety of analyses with
visualization, including differential expression between
groups, coexpression, and outlier sample identification.
Another example is data sharing and analytic platforms
designed to allow a group of investigators with diverse
methodologic expertise to collaborate around a cohort of
patients with several large–scale datasets. These platforms
for joint data analysis and data mining by research con-
sortia, for example, are a critical prerequisite for success-
ful collaboration. One of the several currently available
platforms is tranSMART, which was initially developed
by Johnson and Johnson and subsequently released as
open source software in 2012. It is now supported by the
tranSMART Foundation (transmartfoundation.org) and its
open user community. A research consortium can load
their independently governed tranSMART instance with a
wide variety of data types, including clinical data and ge-
nomic, proteomics, metabolomics, and expression datasets.
Loaded data are then available for a wide range of analyses
(e.g., descriptive statistics, correlations, survival analysis,
clustering, and heat maps). Furthermore, using the same
data–sharing platform across diseases and consortia allows
for more efficient collaboration by scientists with different
expertise and tools inside research teams, and most excit-
ingly, across different research efforts in a globally distrib-
uted manner, while maintaining scientific independence
and control by each participating network.
Examples of Successful Integrative Biology
Approaches in Nephrology
Identification of Disease Etiology: M-Type PLA2R
In the pivotal work to identify M-type PLA2R as an au-
toantigen in idiopathic MN, proteomic work played a crit-
ical role (15). After serum from patients with MN was used
to identify a previously unseen band in extracts of normal
human glomeruli, mass spectrometry proteomics allowed
for identification of candidate peptide sequences contained
in the human protein band extract without prior knowl-
edge. These peptides were then compared with existing
databases of human proteins to narrow to a list of 18 can-
didate proteins. Candidate proteins, in turn, could then be
evaluated against available antibodies and recombinant
proteins, which led to the identification of PLA2R. The
ability to map peptide sequences from this unknown
Western blot band against known proteins is an example
of the value of large-scale data available to inform and
enhance mechanistic laboratory approaches. However,
the MN story of integrating additional genome–scale data-
sets goes even farther. Independent of the immunology
efforts, a genome–wide association study performed on
European patients with MN showed two significant asso-
ciations. One was located, as expected for an autoimmune
disease, in the HLA region, but the second signals tagged
PLA2R as a genetic risk factor for MN, linking genetic risk
with immunopathology in this disease and implicating
PLA2R into the pathophysiology (28). Efforts are under-
way to combine genetics, transcriptomics, proteomic, and
Clin J Am Soc Nephrol 11: 2054–2060, November, 2016 Integrative Biology Approach to Glomerular Disease, Mariani et al. 2057
immunology to define the exact mechanism linking the
genetic polymorphism with the immunopathology (29).
Identification of Progression Risk Factors: Urinary EGF
A data–driven, unbiased approach implemented across
several large–scale data domains recently identified a uri-
nary marker that predicts progression of kidney disease in
three independent cohorts, including two glomerular dis-
ease cohorts (30). The pipeline began with identifying re-
nal biopsy mRNA transcripts that correlated with eGFR
and also were differentially regulated compared with
live kidney donor tissue. Next, the gene list was narrowed
by including those transcripts that underwent validation
in a separate cohort, had kidney-specific expression, and
had compelling biology for a mechanistic role in CKD.
EGF was the top gene transcript meeting these criteria
and is a protein that modulates the response to tubuloin-
terstitial damage. EGF was then evaluated as a potential
noninvasive urine marker in three independent glomerular
disease cohorts. Urine EGF protein level not only corre-
lated with tissue gene expression level but also added
predictive value in predicting progression of CKD above
baseline eGFR, urine albumin, and demographics. It is
proposed that EGF may capture the functional reserve of
the tubulointerstitial compartment not currently captured
by eGFR and urine protein. These results were highlighted
in the NIH Director’s blog as an example of a precision
medicine approach to identifying novel prognostic mark-
ers as well as identifying biologic mechanisms, which can
then be further studied in a more targeted fashion (31).
Identification of Novel Therapeutic Targets: Baricitinib for
Diabetic Nephropathy
A systems-level analysis was to undertaken to better un-
derstand the molecular commonalities and differences in
underlying disease mechanisms between human diabetic
nephropathy and diabetic mouse models, which do not
completely recapitulate the human disease. In two studies,
analysis of kidney tissue mRNA expression in human
diabetic kidney biopsies compared with normal human
samples and diabetic mouse models revealed an associa-
tion of the JAK-STAT pathway expression with human
disease progression (32,33). Baricitinib is a small molecule
inhibitor of JAK-1 and -2, and it was previously approved
for the treatment of rheumatoid arthritis. On the basis of
the human systems–level analysis and prior tissue and an-
imal studies, a phase 2 clinical trial, sponsored by Eli Lilly
(Indianapolis, IN), was conducted in 129 patients. Lower
urinary albumin-to-creatinine ratio was seen at 3 and 6
months in the treatment groups compared with placebo
groups, supporting additional study of baricitinib as a
new therapy for diabetic nephropathy (34). Using ap-
proaches such as these to better understand disease driv-
ers in both human disease and animal models holds
promise for novel treatment design and drug repurposing
in glomerular disease.
Identification of Novel DiagnosticMarkers: Anti-Myeloperoxidase
Autoantibodies in Patients with ANCA-Negative Vasculitis
Although many technologies described here are unbiased
in their approach, there are new immunologic technologies
emerging that allow for clarification of unanswered ques-
tions in a targetedmanner. One such example is a technology
termed autoantigen excision (35). There is a small subset
of patients with pauci–immune necrotizing and crescen-
tic GN who have signs and symptoms consistent with
ANCA-associated GN but whose ANCA serology is negative.
For years, this was a perplexing clinical and serologic discrep-
ancy that resulted in diagnostic and therapeutic delays until
the advent of autoantigen excision. Briefly, this methodology
involves incubation of autoantigen with autoantibody bound
to a protein column, which then is exposed to trypsin, thereby
leaving only the complementarity-determining region of the
autoantigen bound to the antibody followed by mass spec-
trometry for protein identification. The application of autoan-
tigen excision to serum from patients with ANCA-negative
GN resulted in the identification of anti-myeloperoxidase
autoantibodies. Additional studies determined that cerulo-
plasmin, the endogenous inhibitor of myeloperoxidase, was
removed during purification of IgG, which explained why the
standard clinical serum–based ANCA test was negative (35).
Such a methodology and test will not only expedite diagnosis
and treatment of patients with ANCA-negative GN but also,
allow for unbiased identification of autoantigens associated
with other purported humoral autoimmune glomerular
diseases, such as minimal change glomerulopathy and
FSGS, which have autoantigens that remain unknown.
The Road Ahead
Glomerular disease research has made significant prog-
ress in understanding underlying disease mechanisms. In
many patients with inherited glomerular diseases, single-
gene defects with pathologic molecules and pathways have
been defined (36). These specific molecular signals are
now integrated into the larger functional context using com-
prehensive datasets linking genotype to molecular path-
ways, structural lesions, and clinical outcomes. For example,
the interaction of genetic risk loci with steady–state gene
expression profiles and clinical outcomes can be defined
using expression quantitative trait loci, where genetic variants
can be tested for their effect on gene expression variation. This
has been successfully applied for APOL1–associated glomer-
ular disease, lupus nephritis, and CKD (37–40). Linking
genome–wide association study, gene expression, and clini-
cal outcomes allows inferences beyond pure associations to-
ward identification of potential causal disease mechanisms
as therapeutic targets. An intriguing strategy in this context
is the Mendelian randomization approach (i.e., stratifying a
disease population on the basis of a genetic marker closely
linked with a specific molecular function). The subgroups
exhibiting the genetically determined molecular difference
are then evaluated for differences in clinical outcomes us-
ing the genetic variability as the intervention in an in silico
clinical trial.
The approaches above still constrain the analyses to-
ward a predefined set of molecules. A series of computa-
tional strategies has been developed in the field of artificial
intelligence to identify patterns and interdependencies in
multidimensional datasets referred to as machine-learning
approaches. In a variety of biomedical fields, these approaches
are being tested for their utility on large–scale clinical and
genomic datasets. For example, the NIH-International
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Business Machines (IBM)–funded Dialogue for Reverse Engi-
neering Assessments and Methods Challenges provide infor-
mation from a study with genome-scale datasets and outcome
data in an open competition for investigators to develop out-
come or treatment predictor algorithms for the given dataset
(www.dreamchallenges.org). The algorithms from the par-
ticipating scientists compete on a test dataset, and the best
performing algorithms are published and in some instances,
directly used in clinical trials for patient selection (41).
In summary, we are seeing glomerular research tran-
sition to an information-rich science, offering intriguing
opportunities and new challenges. Extracting disease–
relevant, actionable knowledge from the novel big data
sources will be a critical task ahead. Efforts are ongoing
to generate and share high-quality samples and datasets
in globally distributed research networks to define key
drivers of glomerular disease. With access to biopsy tissue
and noninvasive biofluids for molecular profiling strate-
gies, nephrology offers unique opportunities to advance
our molecular understanding of not only glomerular dis-
eases but also chronic diseases in general. With these
advantages in our field, we have to attract the best and
brightest trainees to move precision medicine from labo-
ratory benches and computer hard drives to our nephrology
clinics.
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